摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

acetic acid 1-hydroxy-propyl ester

中文名称
——
中文别名
——
英文名称
acetic acid 1-hydroxy-propyl ester
英文别名
propanediol monoacetate;hydroxypropyl acetate;1-hydroxypropyl acetate
acetic acid 1-hydroxy-propyl ester化学式
CAS
——
化学式
C5H10O3
mdl
——
分子量
118.133
InChiKey
VEGXEWGKYMMJKP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    8
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Triazole oxime derivatives having antimycotic acitivity
    申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
    公开号:EP0670315A1
    公开(公告)日:1995-09-06
    Triazole oxime derivatives represented by the formula (I): (where Ar is a phenyl group substituted by 1 or 2 halogen atoms; R¹ and R² are typically such that, when taken together with the adjacent carbon atom, they form a cyclopropylidene group; R³ is a straight-chained, branched or cyclic alkyl group having 1 - 4 carbon atoms; R⁴ is typically an optionally substituted straight-chained or branched alkyl group having 1 - 4 carbon atoms; and the wavy line represents either an E- or Z-type bond) or salts thereof. The triazole derivatives exhibit a marked therapeutic effects not only in in vitro experiments but also in in vivo experiments using laboratory animal models such as Aspergillus infected mice. The derivatives are also safe to use. Therefore, they are extremely useful as therapeutics for various superficial dermatomycoses, deep dermatomycoses and deep mycoses (mycoses in internal organs).
    Triazole oxime 衍生物的化学式(I)表示为: (其中 Ar 是一个被 1 或 2 个卤素原子取代的苯基;R¹ 和 R² 通常是这样的,当与相邻的碳原子一起时,它们形成一个环丙烯基团;R³ 是一个直链、支链或环状的含有 1 - 4 个碳原子的烷基团;R⁴ 通常是一个可选择取代的直链或支链烷基团,含有 1 - 4 个碳原子;波浪线代表 E- 或 Z- 类型键)或其盐。这些三唑衍生物不仅在体外实验中表现出显著的治疗效果,而且在使用实验动物模型(如感染曲霉的小鼠)进行体内实验时也表现出显著的治疗效果。这些衍生物也是安全的。因此,它们在治疗各种浅表真菌病、深部真菌病和深部真菌病(内脏器官真菌病)方面非常有用。
  • Synthesis of 13-alkyl-gon-4-ones
    申请人:Smith; Herchel
    公开号:US03959322A1
    公开(公告)日:1976-05-25
    The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.
    描述了通过新的全合成方法制备13-甲基孕-4-烯和新型13-聚碳烷基孕-4-烯。通过形成在1,3,5(10),9(11)和14-位置不饱和的四环孕烷结构,选择性地在B和C环中还原,并将所产生的芳香A环化合物转化为孕-4-烯,制备具有孕激素、合成激素和雄激素活性的13-烷基孕-4-烯。
  • Inhibitors of protein isoprenyl transferases
    申请人:University of Pittsburgh
    公开号:US20020193596A1
    公开(公告)日:2002-12-19
    Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.
    具有以下公式的化合物或其药学上可接受的盐,其中R1为(a)氢,(b)较低的烷基,(c)烯基,(d)烷氧基,(e)硫代烷氧基,(f)卤素,(g)卤代烷基,(h)芳基-L2—,以及(i)杂环-L2—;R2从(a)中选择,(b) -C(O)NH-CH(R14)-C(O)OR15,(c)中选择,(d) -C(O)NH-CH(R14)-C(O)NHSO2R16,(e) -C(O)NH-CH(R14)-四唑基,(f) -C(O)NH-杂环,以及(g) -C(O)NH-CH(R14)-C(O)NR17R18;R3为杂环,芳基,取代或未取代的环烷基;R4为氢,较低烷基,卤代烷基,卤素,芳基,芳基烷基,杂环基,或(杂环)烷基;L1为空缺或从(a) -L4-N(R5)-L5-,(b) -L4-O-L5-,(c) -L4-S(O)n-L5-,(d) -L4-L6-C(W)-N(R5)-L5-,(e) -L4-L6-S(O)m-N(R5)-L5-,(f) -L4-N(R5)-C(W)-L7-L5-,(g) -L4-N(R5)-S(O)p-L7-L5-,(h)可选择取代的烷基,(i)可选择取代的烯基,以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
  • 6-substituted purine carbocyclic nucleosides
    申请人:Burroughs Wellcome Co.
    公开号:US05049671A1
    公开(公告)日:1991-09-17
    The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
    本发明涉及6-取代嘌呤环核苷和它们在医学疗法中的应用,特别是在治疗HIV和HBV感染方面。还提供了根据本发明制备化合物的药物配方和工艺。
  • Synthesis of gon-4-enes
    申请人:Smith; Herchel
    公开号:US04002746A1
    公开(公告)日:1977-01-11
    1. A therapeutic composition having progestational activity comprising as active ingredient a 17-aliphatic carboxylic acid ester of 17.alpha.-ethynyl-18-methyl-19-nortestosterone and a pharmaceutical carrier for said compound.
    一种具有孕激素活性的治疗组合物,其活性成分为17-脂肪族羧酸酯的17α-乙炔基-18-甲基-19-去甲睾酮,以及用于该化合物的药用载体。
查看更多